Antitumor Virotherapy by Attenuated Measles Virus (MV)
Abstract
:1. Introduction
2. MV Vaccine
2.1. Measles Virus Description: wt and Vaccine-Attenuated Strains
2.2. Vaccine Efficacy
2.3. Vaccine Safety: Absence of Observed Reversion
3. MV in Antitumor Virotherapy
3.1. Receptors for MV Infection
3.2. MV Sensitivity of Numerous Cancer Types In Vitro and In Vivo
3.3. Engineering of MV to Increase the Efficiency of Antitumor Virotherapy
4. MV and the Antitumor Immune Response
4.1. MV Immunogenicity May Participate in the Efficiency of Antitumor Virotherapy
4.2. MV-Infected Tumor Cells Activate Myeloid Dendritic Cells
4.3. MV-Infected Tumor Cells Activate Plasmacytoid DC (pDC)
4.4. Effects of MV on other Immune Cell Types
4.5. Effects of Anti-Measles Immune Response on MV Antitumor Virotherapy
5. Clinical Trials
5.1. Phase I Clinical Trial on Cutaneous T Cell Lymphoma (CTCL)
5.2. Phase I Clinical Trial on Chemotherapy-Refractory Ovarian Cancer
5.3. Ongoing Clinical Trials
6. Conclusions
Acknowledgements
References and Notes
- Boisgerault, N.; Tangy, F.; Gregoire, M. New perspectives in cancer virotherapy: Bringing the immune system into play. Immunotherapy 2010, 2, 185–199. [Google Scholar] [CrossRef]
- Russell, S.J.; Peng, K.W.; Bell, J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012, 30, 658–670. [Google Scholar] [CrossRef]
- Mogensen, T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009, 22, 240–273, Table of Contents. [Google Scholar] [CrossRef]
- Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392, 245–252. [Google Scholar] [CrossRef]
- Bluming, A.Z.; Ziegler, J.L. Regression of burkitt’s lymphoma in association with measles infection. Lancet 1971, 2, 105–106. [Google Scholar]
- Pasquinucci, G. Possible effect of measles on leukaemia. Lancet 1971, 1, 136. [Google Scholar] [CrossRef]
- Gauvrit, A.; Brandler, S.; Sapede-Peroz, C.; Boisgerault, N.; Tangy, F.; Gregoire, M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific cd8 response. Cancer Res. 2008, 68, 4882–4892. [Google Scholar]
- Guillerme, J.B.; Boisgerault, N.; Roulois, D.; Menager, J.; Combredet, C.; Tangy, F.; Fonteneau, J.-F.; Gregoire, M. Measles virus vaccine-infected tumor cells induce plasmacytoid dendritic cell maturation and tumor antigen cross-presentation. Clin. Cancer Res. 2013, 19, 1147–1158. [Google Scholar] [CrossRef]
- Moss, W.J.; Griffin, D.E. Global measles elimination. Nat. Rev. Microbiol. 2006, 4, 900–908. [Google Scholar] [CrossRef]
- Nomenclature for describing the genetic characteristics of wild-type measles viruses (update). Wkly. Epidemiol. Rec. 2001, 76, 249–251.
- Enders, J.F.; Peebles, T.C. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc. Soc. Exp. Biol. Med. 1954, 86, 277–286. [Google Scholar]
- Bankamp, B.; Takeda, M.; Zhang, Y.; Xu, W.; Rota, P.A. Genetic characterization of measles vaccine strains. J. Infect. Dis. 2011, 204, S533–S548. [Google Scholar] [CrossRef]
- Schwarz, A.J. Preliminary tests of a highly attenuated measles vaccine. Am. J. Dis. Child. 1962, 103, 386–389. [Google Scholar]
- Griffin, D.E.; Pan, C.H.; Moss, W.J. Measles vaccines. Front. Biosci. 2008, 13, 1352–1370. [Google Scholar] [CrossRef]
- World Health Organisation: Immunization, Vaccines and Biologicals: Measles. Available online: http://www.who.int/immunization/topics/measles/en/index.html/ (accessed on 24 April 2012).
- Griffin, D. Measles virus. In Field’s Virology; Knipe, D., Howley, P., Eds.; Lippincott-Raven Publishers: Philadelphia, PA, USA, 2001; Volume 2, pp. 1401–1441. [Google Scholar]
- Lievano, F.; Galea, S.A.; Thornton, M.; Wiedmann, R.T.; Manoff, S.B.; Tran, T.N.; Amin, M.A.; Seminack, M.M.; Vagie, K.A.; Dana, A.; et al. Measles, mumps, and rubella virus vaccine (m-m-rii): A review of 32 years of clinical and postmarketing experience. Vaccine 2012, 30, 6918–6926. [Google Scholar] [CrossRef]
- Parker Fiebelkorn, A.; Redd, S.B.; Gallagher, K.; Rota, P.A.; Rota, J.; Bellini, W.; Seward, J. Measles in the united states during the postelimination era. J. Infect. Dis. 2010, 202, 1520–1528. [Google Scholar] [CrossRef]
- Progress towards measles elimination in who’s european region, 2005–2008. Wkly. Epidemiol. Rec. 2009, 84, 57–64.
- Wolfson, L.J.; Strebel, P.M.; Gacic-Dobo, M.; Hoekstra, E.J.; McFarland, J.W.; Hersh, B.S. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007, 369, 191–200. [Google Scholar]
- Hilleman, M.R. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2001, 20, 651–665. [Google Scholar] [CrossRef]
- Hsu, E.C.; Iorio, C.; Sarangi, F.; Khine, A.A.; Richardson, C.D. Cdw150(slam) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology 2001, 279, 9–21. [Google Scholar] [CrossRef]
- Tatsuo, H.; Ono, N.; Tanaka, K.; Yanagi, Y. Slam (cdw150) is a cellular receptor for measles virus. Nature 2000, 406, 893–897. [Google Scholar]
- Anderson, B.D.; Nakamura, T.; Russell, S.J.; Peng, K.W. High cd46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004, 64, 4919–4926. [Google Scholar] [CrossRef]
- Dorig, R.E.; Marcil, A.; Chopra, A.; Richardson, C.D. The human cd46 molecule is a receptor for measles virus (edmonston strain). Cell 1993, 75, 295–305. [Google Scholar] [CrossRef]
- Naniche, D.; Varior-Krishnan, G.; Cervoni, F.; Wild, T.F.; Rossi, B.; Rabourdin-Combe, C.; Gerlier, D. Human membrane cofactor protein (cd46) acts as a cellular receptor for measles virus. J. Virol. 1993, 67, 6025–6032. [Google Scholar]
- Liszewski, M.K.; Atkinson, J.P. Membrane cofactor protein. Curr. Top. Microbiol. Immunol. 1992, 178, 45–60. [Google Scholar] [CrossRef]
- Fishelson, Z.; Donin, N.; Zell, S.; Schultz, S.; Kirschfink, M. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mcrps) in tumors. Mol. Immunol. 2003, 40, 109–123. [Google Scholar] [CrossRef]
- Ravindranath, N.M.; Shuler, C. Expression of complement restriction factors (cd46, cd55 & cd59) in head and neck squamous cell carcinomas. J. Oral Pathol. Med. 2006, 35, 560–567. [Google Scholar] [CrossRef]
- Peng, K.W.; TenEyck, C.J.; Galanis, E.; Kalli, K.R.; Hartmann, L.C.; Russell, S.J. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002, 62, 4656–4662. [Google Scholar]
- Noyce, R.S.; Bondre, D.G.; Ha, M.N.; Lin, L.T.; Sisson, G.; Tsao, M.S.; Richardson, C.D. Tumor cell marker pvrl4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 2011, 7, e1002240. [Google Scholar] [CrossRef]
- Muhlebach, M.D.; Mateo, M.; Sinn, P.L.; Prufer, S.; Uhlig, K.M.; Leonard, V.H.; Navaratnarajah, C.K.; Frenzke, M.; Wong, X.X.; Sawatsky, B.; et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011, 480, 530–533. [Google Scholar]
- Racaniello, V. Virology. An exit strategy for measles virus. Science 2011, 334, 1650–1651. [Google Scholar] [CrossRef]
- Mendelsohn, C.L.; Wimmer, E.; Racaniello, V.R. Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 1989, 56, 855–865. [Google Scholar] [CrossRef]
- Lopez, M.; Cocchi, F.; Menotti, L.; Avitabile, E.; Dubreuil, P.; Campadelli-Fiume, G. Nectin2alpha (prr2alpha or hveb) and nectin2delta are low-efficiency mediators for entry of herpes simplex virus mutants carrying the leu25pro substitution in glycoprotein d. J. Virol. 2000, 74, 1267–1274. [Google Scholar]
- Derycke, M.S.; Pambuccian, S.E.; Gilks, C.B.; Kalloger, S.E.; Ghidouche, A.; Lopez, M.; Bliss, R.L.; Geller, M.A.; Argenta, P.A.; Harrington, K.M.; et al. Nectin 4 overexpression in ovarian cancer tissues and serum: Potential role as a serum biomarker. Am. J. Clin. Pathol. 2010, 134, 835–845. [Google Scholar] [CrossRef]
- Takano, A.; Ishikawa, N.; Nishino, R.; Masuda, K.; Yasui, W.; Inai, K.; Nishimura, H.; Ito, H.; Nakayama, H.; Miyagi, Y.; et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009, 69, 6694–6703. [Google Scholar] [CrossRef]
- Fabre-Lafay, S.; Garrido-Urbani, S.; Reymond, N.; Goncalves, A.; Dubreuil, P.; Lopez, M. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (tace)/adam-17. J. Biol. Chem. 2005, 280, 19543–19550. [Google Scholar]
- Sugiyama, T.; Yoneda, M.; Kuraishi, T.; Hattori, S.; Inoue, Y.; Sato, H.; Kai, C. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Gene Ther. 2012, 20, 338–347. [Google Scholar]
- Boisgerault, N.; Fonteneau, J.F.; Gregoire, M. INSERM UMR892: Nantes, France; Unpublished work. 2011. [Google Scholar]
- Parrula, C.; Fernandez, S.A.; Zimmerman, B.; Lairmore, M.; Niewiesk, S. Measles virotherapy in a mouse model of adult t-cell leukaemia/lymphoma. J. Gen. Virol. 2011, 92, 1458–1466. [Google Scholar] [CrossRef]
- Grote, D.; Russell, S.J.; Cornu, T.I.; Cattaneo, R.; Vile, R.; Poland, G.A.; Fielding, A.K. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001, 97, 3746–3754. [Google Scholar] [CrossRef]
- Peng, K.W.; Ahmann, G.J.; Pham, L.; Greipp, P.R.; Cattaneo, R.; Russell, S.J. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001, 98, 2002–2007. [Google Scholar] [CrossRef]
- Penheiter, A.R.; Wegman, T.R.; Classic, K.L.; Dingli, D.; Bender, C.E.; Russell, S.J.; Carlson, S.K. Sodium iodide symporter (nis)-mediated radiovirotherapy for pancreatic cancer. AJR Am. J. Roentgenol. 2010, 195, 341–349. [Google Scholar] [CrossRef]
- Allen, C.; Opyrchal, M.; Aderca, I.; Schroeder, M.A.; Sarkaria, J.N.; Domingo, E.; Federspiel, M.J.; Galanis, E. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther. 2012, 122, 745–754. [Google Scholar]
- Phuong, L.K.; Allen, C.; Peng, K.W.; Giannini, C.; Greiner, S.; TenEyck, C.J.; Mishra, P.K.; Macura, S.I.; Russell, S.J.; Galanis, E.C. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003, 63, 2462–2469. [Google Scholar]
- Iankov, I.D.; Msaouel, P.; Allen, C.; Federspiel, M.J.; Bulur, P.A.; Dietz, A.B.; Gastineau, D.; Ikeda, Y.; Ingle, J.N.; Russell, S.J.; et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res. Treat. 2010, 122, 745–754. [Google Scholar] [CrossRef]
- McDonald, C.J.; Erlichman, C.; Ingle, J.N.; Rosales, G.A.; Allen, C.; Greiner, S.M.; Harvey, M.E.; Zollman, P.J.; Russell, S.J.; Galanis, E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat. 2006, 99, 177–184. [Google Scholar]
- Donnelly, O.G.; Errington-Mais, F.; Steele, L.; Hadac, E.; Jennings, V.; Scott, K.; Peach, H.; Phillips, R.M.; Bond, J.; Pandha, H.; et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2011, 20, 7–15. [Google Scholar]
- Meng, X.; Nakamura, T.; Okazaki, T.; Inoue, H.; Takahashi, A.; Miyamoto, S.; Sakaguchi, G.; Eto, M.; Naito, S.; Takeda, M.; et al. Enhanced antitumor effects of an engineered measles virus edmonston strain expressing the wild-type n, p, l genes on human renal cell carcinoma. Mol. Ther. 2010, 18, 544–551. [Google Scholar] [CrossRef]
- Li, H.; Peng, K.W.; Dingli, D.; Kratzke, R.A.; Russell, S.J. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 2010, 17, 550–558. [Google Scholar] [CrossRef]
- Hutzen, B.; Pierson, C.R.; Russell, S.J.; Galanis, E.; Raffel, C.; Studebaker, A.W. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. BMC Cancer 2012, 12, 508. [Google Scholar] [CrossRef]
- Studebaker, A.W.; Kreofsky, C.R.; Pierson, C.R.; Russell, S.J.; Galanis, E.; Raffel, C. Treatment of medulloblastoma with a modified measles virus. Neuro. Oncol. 2010, 12, 1034–1042. [Google Scholar] [CrossRef]
- Boisgerault, N.; Guillerme, J.B.; Pouliquen, D.; Achard, C.; Mesel-Lemoine, M.; Combredet, C.; Fonteneau, J.F.; Tangy, F.; Gregoire, M. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. BioMed Res. Int. 2013, 2013, 387362. [Google Scholar]
- Zhang, S.C.; Wang, W.L.; Cai, W.S.; Jiang, K.L.; Yuan, Z.W. Engineered measles virus edmonston strain used as a novel oncolytic viral system against human hepatoblastoma. BMC Cancer 2012, 12, 427. [Google Scholar] [CrossRef]
- Tangy, F.; Naim, H.Y. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol. 2005, 18, 317–326. [Google Scholar] [CrossRef]
- Greiner, A.; Neumann, M.; Stingl, S.; Wassink, S.; Marx, A.; Riechert, F.; Muller-Hermelink, H.K. Characterization of wue-1, a novel monoclonal antibody that stimulates the growth of plasmacytoma cell lines. Virchows. Arch. 2000, 437, 372–379. [Google Scholar] [CrossRef]
- Hummel, H.D.; Kuntz, G.; Russell, S.J.; Nakamura, T.; Greiner, A.; Einsele, H.; Topp, M.S. Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells. J. Gen. Virol. 2009, 90, 693–701. [Google Scholar] [CrossRef]
- Myers, R.; Greiner, S.; Harvey, M.; Soeffker, D.; Frenzke, M.; Abraham, K.; Shaw, A.; Rozenblatt, S.; Federspiel, M.J.; Russell, S.J.; et al. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther. 2005, 12, 593–599. [Google Scholar] [CrossRef]
- Galanis, E.; Hartmann, L.C.; Cliby, W.A.; Long, H.J.; Peethambaram, P.P.; Barrette, B.A.; Kaur, J.S.; Haluska, P.J., Jr.; Aderca, I.; Zollman, P.J.; et al. Phase i trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010, 70, 875–882. [Google Scholar] [CrossRef]
- Dingli, D.; Peng, K.W.; Harvey, M.E.; Greipp, P.R.; O’Connor, M.K.; Cattaneo, R.; Morris, J.C.; Russell, S.J. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103, 1641–1646. [Google Scholar] [CrossRef]
- Brem, H.; Gresser, I.; Grosfeld, J.; Folkman, J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J. Pediatr. Surg. 1993, 28, 1253–1257. [Google Scholar] [CrossRef]
- Le Bon, A.; Tough, D.F. Links between innate and adaptive immunity via type i interferon. Curr. Opin. Immunol. 2002, 14, 432–436. [Google Scholar] [CrossRef]
- Berchtold, S.; Lampe, J.; Weiland, T.; Smirnow, I.; Schleicher, S.; Handgretinger, R.; Kopp, H.G.; Reiser, J.; Stubenrauch, F.; Mayer, N.; et al. Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis. J. Virol. 2013, 87, 3484–3501. [Google Scholar] [CrossRef]
- Prestwich, R.J.; Ilett, E.J.; Errington, F.; Diaz, R.M.; Steele, L.P.; Kottke, T.; Thompson, J.; Galivo, F.; Harrington, K.J.; Pandha, H.S.; et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin. Cancer Res. 2009, 15, 4374–4381. [Google Scholar] [CrossRef]
- Errington, F.; Steele, L.; Prestwich, R.; Harrington, K.J.; Pandha, H.S.; Vidal, L.; de Bono, J.; Selby, P.; Coffey, M.; Vile, R.; et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J. Immunol. 2008, 180, 6018–6026. [Google Scholar]
- Kepp, O.; Tesniere, A.; Zitvogel, L.; Kroemer, G. The immunogenicity of tumor cell death. Curr. Opin. Oncol. 2009, 21, 71–76. [Google Scholar] [CrossRef]
- Kumar, H.; Kawai, T.; Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 2011, 30, 16–34. [Google Scholar] [CrossRef]
- Steinman, R.M. Decisions about dendritic cells: Past, present, and future. Annu. Rev. Immunol. 2012, 30, 1–22. [Google Scholar] [CrossRef]
- Steinman, R.M.; Lustig, D.S.; Cohn, Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J. Exp. Med. 1974, 139, 1431–1445. [Google Scholar] [CrossRef]
- Joffre, O.P.; Segura, E.; Savina, A.; Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 2012, 12, 557–569. [Google Scholar] [CrossRef]
- Fujii, S.; Liu, K.; Smith, C.; Bonito, A.J.; Steinman, R.M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires cd40 ligation in addition to antigen presentation and cd80/86 costimulation. J. Exp. Med. 2004, 199, 1607–1618. [Google Scholar] [CrossRef]
- Krysko, D.V.; Garg, A.D.; Kaczmarek, A.; Krysko, O.; Agostinis, P.; Vandenabeele, P. Immunogenic cell death and damps in cancer therapy. Nat. Rev. Cancer 2012, 12, 860–875. [Google Scholar] [CrossRef]
- Bachem, A.; Guttler, S.; Hartung, E.; Ebstein, F.; Schaefer, M.; Tannert, A.; Salama, A.; Movassaghi, K.; Opitz, C.; Mages, H.W.; et al. Superior antigen cross-presentation and xcr1 expression define human cd11c+cd141+ cells as homologues of mouse cd8+ dendritic cells. J. Exp. Med. 2010, 207, 1273–1281. [Google Scholar] [CrossRef]
- Crozat, K.; Guiton, R.; Contreras, V.; Feuillet, V.; Dutertre, C.A.; Ventre, E.; Vu Manh, T.P.; Baranek, T.; Storset, A.K.; Marvel, J.; et al. The xc chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse cd8alpha+ dendritic cells. J. Exp. Med. 2010, 207, 1283–1292. [Google Scholar] [CrossRef]
- Jongbloed, S.L.; Kassianos, A.J.; McDonald, K.J.; Clark, G.J.; Ju, X.; Angel, C.E.; Chen, C.J.; Dunbar, P.R.; Wadley, R.B.; Jeet, V.; et al. Human cd141+ (bdca-3)+ dendritic cells (dcs) represent a unique myeloid dc subset that cross-presents necrotic cell antigens. J. Exp. Med. 2010, 207, 1247–1260. [Google Scholar] [CrossRef] [Green Version]
- Poulin, L.F.; Salio, M.; Griessinger, E.; Anjos-Afonso, F.; Craciun, L.; Chen, J.L.; Keller, A.M.; Joffre, O.; Zelenay, S.; Nye, E.; et al. Characterization of human dngr-1+ bdca3+ leukocytes as putative equivalents of mouse cd8alpha+ dendritic cells. J. Exp. Med. 2010, 207, 1261–1271. [Google Scholar] [CrossRef]
- Fonteneau, J.F.; Gilliet, M.; Larsson, M.; Dasilva, I.; Munz, C.; Liu, Y.J.; Bhardwaj, N. Activation of influenza virus-specific cd4+ and cd8+ t cells: A new role for plasmacytoid dendritic cells in adaptive immunity. Blood 2003, 101, 3520–3526. [Google Scholar] [CrossRef]
- Di Pucchio, T.; Chatterjee, B.; Smed-Sorensen, A.; Clayton, S.; Palazzo, A.; Montes, M.; Xue, Y.; Mellman, I.; Banchereau, J.; Connolly, J.E. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class i. Nat. Immunol. 2008, 9, 551–557. [Google Scholar] [CrossRef]
- Hoeffel, G.; Ripoche, A.C.; Matheoud, D.; Nascimbeni, M.; Escriou, N.; Lebon, P.; Heshmati, F.; Guillet, J.G.; Gannage, M.; Caillat-Zucman, S.; et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 2007, 27, 481–492. [Google Scholar] [CrossRef]
- Diamond, M.S.; Kinder, M.; Matsushita, H.; Mashayekhi, M.; Dunn, G.P.; Archambault, J.M.; Lee, H.; Arthur, C.D.; White, J.M.; Kalinke, U.; et al. Type i interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208, 1989–2003. [Google Scholar] [CrossRef]
- Fuertes, M.B.; Kacha, A.K.; Kline, J.; Woo, S.R.; Kranz, D.M.; Murphy, K.M.; Gajewski, T.F. Host type i ifn signals are required for antitumor cd8+ t cell responses through cd8{alpha}+ dendritic cells. J. Exp. Med. 2011, 208, 2005–2016. [Google Scholar] [CrossRef]
- Drobits, B.; Holcmann, M.; Amberg, N.; Swiecki, M.; Grundtner, R.; Hammer, M.; Colonna, M.; Sibilia, M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pdcs into tumor-killing effector cells. J. Clin. Invest. 2012, 122, 575–585. [Google Scholar] [CrossRef]
- Liu, C.; Lou, Y.; Lizee, G.; Qin, H.; Liu, S.; Rabinovich, B.; Kim, G.J.; Wang, Y.H.; Ye, Y.; Sikora, A.G.; et al. Plasmacytoid dendritic cells induce nk cell-dependent, tumor antigen-specific t cell cross-priming and tumor regression in mice. J. Clin. Invest. 2008, 118, 1165–1175. [Google Scholar]
- Mouries, J.; Moron, G.; Schlecht, G.; Escriou, N.; Dadaglio, G.; Leclerc, C. Plasmacytoid dendritic cells efficiently cross-prime naive t cells in vivo after tlr activation. Blood 2008, 112, 3713–3722. [Google Scholar] [CrossRef]
- Tel, J.; Aarntzen, E.H.; Baba, T.; Schreibelt, G.; Schulte, B.M.; Benitez-Ribas, D.; Boerman, O.C.; Croockewit, S.; Oyen, W.J.; van Rossum, M.; et al. Natural human plasmacytoid dendritic cells induce antigen-specific t-cell responses in melanoma patients. Cancer Res. 2013, 73, 1063–1075. [Google Scholar] [CrossRef]
- Grote, D.; Cattaneo, R.; Fielding, A.K. Neutrophils contribute to the measles virus-induced antitumor effect: Enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res. 2003, 63, 6463–6468. [Google Scholar]
- Liu, C.; Russell, S.J.; Peng, K.W. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol. Ther. 2010, 18, 1155–1164. [Google Scholar] [CrossRef]
- Mader, E.K.; Maeyama, Y.; Lin, Y.; Butler, G.W.; Russell, H.M.; Galanis, E.; Russell, S.J.; Dietz, A.B.; Peng, K.W. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res. 2009, 15, 7246–7255. [Google Scholar] [CrossRef]
- Heo, J.; Reid, T.; Ruo, L.; Breitbach, C.J.; Rose, S.; Bloomston, M.; Cho, M.; Lim, H.Y.; Chung, H.C.; Kim, C.W.; et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia jx-594 in liver cancer. Nat. Med. 2013, 19, 329–336. [Google Scholar] [CrossRef]
- Taqi, A.M.; Abdurrahman, M.B.; Yakubu, A.M.; Fleming, A.F. Regression of Hodgkin’s disease after measles. Lancet 1981, 1, 1112. [Google Scholar]
- Zygiert, Z. Hodgkin’s disease: Remissions after measles. Lancet 1971, 1, 593. [Google Scholar] [CrossRef]
- Ziegler, J.L. Spontaneous remission in burkitt’s lymphoma. Natl. Cancer Inst. Monogr. 1976, 44, 61–65. [Google Scholar]
- Heinzerling, L.; Kunzi, V.; Oberholzer, P.A.; Kundig, T.; Naim, H.; Dummer, R. Oncolytic measles virus in cutaneous t-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005, 106, 2287–2294. [Google Scholar] [CrossRef]
- ClinicalTrials.gov. Available online: http://www.clinicaltrials.gov/ (accessed on 12 December 2012).
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Guillerme, J.-B.; Gregoire, M.; Tangy, F.; Fonteneau, J.-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology 2013, 2, 587-602. https://doi.org/10.3390/biology2020587
Guillerme J-B, Gregoire M, Tangy F, Fonteneau J-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology. 2013; 2(2):587-602. https://doi.org/10.3390/biology2020587
Chicago/Turabian StyleGuillerme, Jean-Baptiste, Marc Gregoire, Frédéric Tangy, and Jean-François Fonteneau. 2013. "Antitumor Virotherapy by Attenuated Measles Virus (MV)" Biology 2, no. 2: 587-602. https://doi.org/10.3390/biology2020587